Perjeta 420 MG/14 ML vial 14ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMDZ4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $46,510
Award facts
- Contract value 100% obligated
- $46,509.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $46,509.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The delivery order, issued on December 2, 2025, with an ultimate completion date of December 23, 2025, carries no set-aside designation, indicating the award was made through unrestricted federal procurement. DMS Pharmaceutical Group was selected as the awardee under its existing Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors for comprehensive pharmaceutical supply to Department of Defense medical facilities worldwide.
This delivery order represents a single transaction within DMS Pharmaceutical Group's broader role as a critical pharmaceutical supplier under the PPV-G GEN V program, which authorizes DLA to issue firm fixed-price orders for branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables. The company's established performance across numerous prior delivery orders for specialized pharmaceutical products, including oncology treatments and biologic agents, demonstrates its capability to fulfill the diverse medical supply requirements of military healthcare operations. As a single-award IDC holder with a ceiling value of $499,999,999 extending through December 31, 2036, DMS Pharmaceutical Group is positioned to serve as a primary pharmaceutical supplier supporting Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FMDZ4?
SPE2DR26FMDZ4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 2, 2025.
How much is contract SPE2DR26FMDZ4 worth?
The government has obligated $46,510 on SPE2DR26FMDZ4.
Is contract SPE2DR26FMDZ4 an order under another contract?
Yes. SPE2DR26FMDZ4 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDZ4 competed?
The extent of competition for SPE2DR26FMDZ4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award